Ironman Competitor Unable to Complete Race Lends a Hand, Finishes a Hero

NU-9 Is Now AKV9, and Doing Well in Preclinical Studies

AKAVA Therapeutics’ experimental therapy AKV9, formerly NU-9, was superior to approved therapies for amyotrophic lateral sclerosis (ALS) at improving the health of lab-grown upper motor neurons from a mouse model of the disease, a study shows. Upper motor neurons are one of the two types of specialized nerve cells that…

When There Isn’t Time to See a Tree Grow

As I left our house to get the kids from school, the tree was gone. A contractor’s crew was removing brush from the ditch with an excavator to extend the culvert that passed under our driveway. My husband, Todd, had specifically asked that the poplar tree be left alone. I…

CNM-Au8 Extends Survival, RESCUE-ALS Study Suggests

Treatment with the experimental gold nanocrystal therapy CNM-Au8 decreased the risk of mortality by 64% among people with early amyotrophic lateral sclerosis (ALS), compared to what would be expected without treatment, according to new analyses from the RESCUE-ALS clinical trial. The findings were presented by Clene Nanomedicine,…

Starting Tofersen Early Slows ALS Progression Better: Trial Data

Early use of Biogen’s tofersen significantly slows disability progression, as well as a decline in lung function, muscle strength, and quality of life in amyotrophic lateral sclerosis (ALS) patients with mutations in the SOD1 gene, compared with a six-month delay in starting treatment. These benefits were accompanied by pronounced and sustained…